Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying Opportunity
Ultragenyx Pharmaceutical (RARE) sold a Rare Pediatric Disease Priority Review Voucher for $210M, according to the company. Proceeds will support rare-disease programs. RARE shares rose 4% at the time of writing, despite broader market declines. This is Ultragenyx's third PRV sale, with previous sales in 2018 totaling $210.6M.
How this was made
The 30-second read
Why it matters
The transaction provides significant non‑dilutive capital, supporting pipeline advancement and improving short‑term share price momentum.
Market read
The $210 M voucher sale is a primary corporate action that moved the stock up 4% intraday, offering a clear short‑term trading catalyst.
What to watch
The $210 M proceeds are a one‑time boost; ongoing cash burn and pipeline risk remain.
Background
Ultragenyx Pharmaceutical (RARE) announced its third Priority Review Voucher sale, raising $210 million to fund rare‑disease programs.
Ticker impact
Ultragenyx Pharmaceutical sold a rare‑disease Priority Review Voucher for $210 million, providing non‑dilutive capital to fund its pipeline.
likely upward pressure as investors price in the $210 M non‑dilutive capital raise
Large, first‑report capital raise; stock already up ~4% on the news, indicating market absorption.
Market effects
Adds cash to the rare‑disease biotech sector, potentially prompting re‑rating of peers.
U.S. biotech market may see modest uplift from the transaction.
Limited to biotech investors; no broad market effect.
Counterpoint
Some investors may view the voucher sale as a sign that Ultragenyx lacks near‑term product revenue.
Key entities
- companyUltragenyx Pharmaceutical
Biotech firm focused on rare‑disease therapies, ticker RARE.
- assetPriority Review Voucher
FDA‑issued voucher that can accelerate drug review or be sold to other companies.
